The Food and Drug Administration (FDA) has granted 510(k) clearance for Vesalio’s enVast clot retriever, paving the way for its commercial launch in the US.
The device is said to be the first clot retriever...
The Food and Drug Administration (FDA) has granted 510(k) clearance for Vesalio’s enVast clot retriever, paving the way for its commercial launch in the...
The FDA has granted Breakthrough Device Designation to Nephrodite’s Holly implantable continuous dialysis system.
In an exclusive interview ahead of the official announcement, Nephrodite co-founder...
Strategic capital and acquisitions are driving rapid progress across multiple therapeutic and diagnostic areas. With funding flowing into neuromodulation, AI diagnostics, surgical robotics, and...
Subsense, a developer of non-surgical invasive, nanoparticle-based brain-computer interfaces (BCIs), has added $10 million in new capital following positive early breakthroughs, bringing total funding...
JenaValve announced new results from an expanded patient cohort supporting the use of its Trilogy transcatheter heart valve (THV) system.
Results from the ALIGN-AR pivotal...
Vexev and U.S. Renal Care announced successful results from the CANSCAN trial of the VxWave robotic ultrasound imaging system. Sydney, Australia-based Vexev develops the...
Hyperion Surgical announced today that it completed the world’s first robotic-assisted intravenous (IV) catheterisation using its Ivy platform.
Ivy integrates advanced imaging, AI and robotic...
AtriCure, a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced...
The Food and Drug Administration (FDA) has granted 510(k) clearance for Vesalio’s enVast clot retriever, paving the way for its commercial launch in the...
The FDA has granted Breakthrough Device Designation to Nephrodite’s Holly implantable continuous dialysis system.
In an exclusive interview ahead of the official announcement, Nephrodite co-founder...
Strategic capital and acquisitions are driving rapid progress across multiple therapeutic and diagnostic areas. With funding flowing into neuromodulation, AI diagnostics, surgical robotics, and...
Subsense, a developer of non-surgical invasive, nanoparticle-based brain-computer interfaces (BCIs), has added $10 million in new capital following positive early breakthroughs, bringing total funding...